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Abstract
Background: Type B insulin resistance is a rare autoimmune disease characterized by the presence of autoantibodies
against the insulin receptor. Helicobacter pylori (H pylori) infection may play a causative role in the autoimmune
diseases.
Case presentation: Here, we present a rare case of a 48-year old female patient, who had type B insulin resistance
with systemic scleroderma and was successfully treated with multiple immune suppressants after eradication of
Helicobacter pylori infection.
Conclusion: The present case suggests H pylori infection-related pathological mechanism may contribute to type
B insulin resistance syndrome and autoimmune disorders. Treatment toward H pylori may be helpful to relieve
syndrome of type B insulin resistance for H pylori positive patients.
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Background
Type B insulin resistance is a rare autoimmune disease
characterized by the presence of anti-insulin receptor anti-
bodies, which impair the binding of insulin to its receptor
and cause severe insulin resistance (IR) [1, 2]. The major-
ity of patients present with severe hyperglycemia and
extreme insulin resistance because of the insulin receptor-
antagonizing action of the autoantibodies, but some
patients may present with hypoglycemia due to agonist ac-
tivity of anti-insulin receptor antibodies [3]. Type B insulin
resistance often occurs to patients with autoimmune
diseases, such as systemic sclerosis, systemic lupus
erythematosus and Sjogren’s syndrome [1]. The exact eti-
ology of these autoimmune diseases remains unclear, but
it has long been suggested that exposure to certain
environmental agents, such as viral and bacterial infection,
in genetically susceptible individuals may be the catalyst
for the initiation of autoimmune processes [4, 5]. Helico-
bacter pylori (H pylori) infection can affect the host im-
mune response by a number of means and may play a
causative role in the autoimmune diseases [4]. Thus, ther-
apy focusing on the elimination of H pylori may be helpful
to induce the remission of these autoimmune diseases. In
this report, we describe the clinical course of a female pa-
tient with type B insulin resistance and scleroderma, who
was successfully treated with multiple immunosuppres-
sants after eradication of H pylori infection.
Case presentation
A 48-year-old Chinese woman presented with polydipsia
and polyuria in January 2011. Her fasting blood glucose
(FBG) and postprandial blood glucose (PBG) were
5.41 mmol/L and 25.79 mmol/L respectively and HbA1c
was 11.9 % (normal range 4.1–6.5 %). On physical
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examination, her weight was 43 kg, height 149 cm, BMI
19.4 kg/m2. She had no family history of diabetes. The
patient was initially diagnosed as type 2 diabetes
followed treatment with metformin, pioglitazone and
acarbose. The treatment did not relieve her symptoms
and her blood glucose could not be controlled.
The patient also complained of Raynaud’s phenomenon
and morning stiffness in the joints of her both hands in
the past 2 years. Skin hardening was observed in her
hands, and her fingers were swollen and hard to flex. The
first admission laboratory tests were shown in Table 1.
Her liver function and kidney function were normal.
Erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP) and rheumatoid factor were in normal range. γ-
globulin was 30.4 %(11.1–18.8 %. Serological data showed
increased levels of IgG and Ig E, decreased levels of serum
C3, and positive antinuclear antibodies (1:1000). Anti-
glutamic acid decarboxylase (GAD) and anti-insulin anti-
bodies were negative, but anti-insulin receptor antibodies
were detected (ELISA, Abcam, China) (strong positive).
The response to a 75-g oral glucose tolerance test (75 g-
OGTT) was clearly abnormal (Table 2) with marked
hyperglycemia and hyperinsulinemia. Leptin and adipo-
nectin levels were 16 pg/mL(102 ± 8 9 pg/mL) and
35.8 ng/mL (5.6 ± 3.2 ng/mL) respectively. Microcircula-
tion nailfold test showed the decreased number of
Table 1 Biochemical and Serological Evaluation
Item 1st admission 2nd admission 3rd admission Reference range (Unit)
Platelets 110 154 130 109/L
Creatinine 36.3 33.8 39.9 44–106 μmol/l
Total protein 67.0 65.7 66.2 55–80 g/L
Albumin 30.7 36.4 39 35–50 g/L
ALT 23.4 29.5 15.5 0–35 U/L
AST 19.1 19.7 19.6 0–35 U/L
Cholesterol 2.88 2.88 2.79 3.1–5.7 mmol/L
Triglyceride 0.56 0.56 0.48 0.4–1.7 mmol/L
LDL-C 0.88 1.79 1.05 mmol/L
HDL-C 1.46 1.02 1.59 mmol/L
IGF-1 25 — — 116–358 ng
TT4 95.6 69.6 66.0 55.3–160.88 nmol/L
FT4 9.63 10.4 10.66 10.42–24.62 pmol/L
TT3 0.79 0.68 1.03 1.01–2.95 nmol/L
FT3 2.46 2.19 3.33 2.76–6.3 pmol/L
TSH 0.80 0.55 0.66 0.35–5.5 mU/L
TgAb 95.2 32.8 10.5 <60 IU/L
TPOAb 105.2 101.1 21.8 <60 IU/L
UFC 198.7 — – 153.2–789.4 mmol/24 h
FSH 3.91 2.02 1.5–33.4 IU/L
LH 0.55 0.15 0.5–76.3mIU/ml
Testosterone 1.22 1.07 0.5–2.6 nmol/L
ICA negative – – Negative
IAA negative — – Negative
GAD negative — – Negative
INSR antibody Positive (+++) Negative Negative
DOB(Urea breath test) – 19.7 0 ≤4.0
IgE 1630 887 523 0–100 IU/ml
IgG 1960 1720 1650 700–1600 mg/ml
C3 29.8 56.5 73.3 90–180 mg/dl
C4 12.9 13.4 14.9 10–40 mg/dl
ANA 1:1000 >1:1000 1:640 Negative
DOB delta over baseline, TPO-Ab antithyroid peroxydase antibody, Tg-Ab antithyroglobulin antibody, ANA Antinuclear antibodies
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microvessels and irregularly enlarged loops and capillary
hemorrhage in her both hands. According to the above
manifestations, the patient was diagnosed with type B in-
sulin resistance with Scleroderma.
Anti-hyperglycemic agents were initiated, but there
was minimal response to multiple oral medications given
at high doses, including glymepiride 6 mg/day, metfor-
min 2.0 g/day, and pioglitazone 30 mg/day. Insulin ther-
apy was added, but her blood glucose was higher than
15 mmol/L in the daytime despite that doses were up to
18,000 units/day with continuous insulin (including hu-
man regular insulin and rapid-acting insulin) infusion.
Methylprednisolone (600 mg/day) was infused for 3 days,
followed by prednisone (30 mg/d) and azathioprine
(100 mg/d). After 4 weeks, prednisone dose was grad-
ually reduced by 5 mg weekly until a 5-mg maintenance
dose was reached, followed by an additional 8 weeks in
maintenance dose. These drugs were withdrawn after
16 weeks. Glymepiride, metformin, and pioglitazone
were continued, and subcutaneous insulin injections
were prescribed (regular human insulin 20 U before
every meals, and NPH 10U at bedtime).
In her second hospitalization in May 2012, her HbA1c
was elevated at 15.3 %. She complained stomachache,
and H pylori infection was diagnosed based on the
carbon-13 urea breath test. She was treated with quadru-
ple eradication therapy (amoxicillin, esomeprazole, clari-
thromycin and bismuth potassium citrate) for 2 weeks.
Her immunosuppressive therapy switched to triptery-
gium 20 mg tid,azathioprine (100 mg/d) and cyclophos-
phamide 60 mg/d (Fig. 1). Thereafter, the skin lesion of
hands and Raynaud’s phenomenon improved gradually.
Meantime, her glycemic control began to improve.
HbA1c was decreased to 10.6 and 8.7 % on August and
December 2012 respectively, without hypoglycemic epi-
sodes. Carbon-13 urea breath test was repeated in Dec
2012 and the result was negative. In the beginning of
2013, she experienced hypoglycemic symptoms, with
blood glucose levels between 3.4 to 4.6 mmol/L.
In March 2013, on her third admission, all biochemical
and serological parameters were repeated (Table 1). Her
HbA1c levels were normal at 5.9 % though 75-g OGTT
(Table 2) showed that the hyperglycemia and hyperinsu-
linemia were improved significantly. Repeated insulin
receptor antibody testing revealed that her insulin recep-
tor antibody had become negative. Serological data
showed that Ig G, Ig E and complement levels were near
normal, and titer of antinuclear antibodies was de-
creased. Urea breath test of H pylori remained negative.
At further follow-up, the patient remained euglycemic
and no any anti-hyperglycemia therapy was prescribed.
Conclusions
The case presents a patient who had extremely high en-
dogenous insulin secretion but remained hyperglycemic
(glucose levels 16.7–27.8 mmol/l) even on intravenous
insulin (either regular or aspart) doses as high as 18,000
U/day, thus she had severe insulin resistance. There are
two syndromes associated with severe insulin resistance,
type A and type B. Type A insulin resistance syndrome
is a genetic disease resulting from mutations in the
insulin receptor gene. Type B insulin resistance is caused
by autoantibody directed against the insulin receptor.
The diagnosis of type B insulin resistance syndrome is
based on the presence of hyperglycemia (sometimes
hypoglycemia paradoxically), hyperinsulinemia and posi-
tive insulin receptor antibodies. Our patient presented
with severe hyperglycemia and hyperinsulinemia, and
Table 2 Pre- and post-treatment serum levels of blood glucose, insulin and C-peptide after 75 g oral glucose tolerance test
0 min 60 min 120 min
Pre-treatment Post treatment Pre-treatment Post treatment Pre-treatment Post treatment
Blood glucose (mmol/L) 4.47 6.45 13.56 7.46 17.51 8.56
Seruminsulin (mU/L) 118.7 10.57 192.1 145.5 452.7 235
C-peptide(ng/mL) 1.33 0.87 2.65 1.79 6.78 3.69
Fig. 1 Various immunosuppressive therapies for the patient over time
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her other clinical features were also consistent with type
B insulin resistance described by Arioglu E et al. [1].
Besides, the diagnosis of type B insulin resistance was
confirmed by the presence of insulin receptor antibody.
Type B insulin resistance syndrome is frequently asso-
ciated with other autoimmune diseases. Based on litera-
ture review, there have been only one case report of type
B insulin resistance associated with scleroderma [6].
Scleroderma (Systemic sclerosis) is a heterogeneous dis-
ease typically presented with 3 hallmarks: small vessel
vasculopathy, production of autoantibodies, and fibro-
blast dysfunction leading to increased deposition of
extracellular matrix [7]. Typical scleroderma is classically
defined as symmetrical skin thickening, with Raynaud’s
phenomenon presented in about 90 % of cases, nail-fold
capillary changes, and antinuclear antibodies [7]. Sys-
temic involvement may or may not be present. Add-
itional symptoms of scleroderma typically present with
two years’ Raynaud’s phenomenon. In our case, the pa-
tient had typical skin changes, nail-fold capillary abnor-
malities, antinuclear antibodies detected by biochemical
and serologic tests, elevated Ig E and Ig G, and low level
of complement (C3). These manifestos collectively led to
the diagnosis of scleroderma according to ACR/EULAR
(American College of Rheumatology/European League
Against Rheumatism) classification criteria of systemic
sclerosis [8]. So it was confirmed that type B insulin
resistance and scleroderma occurred concomitantly.
However, the mechanisms for the development of anti-
insulin-receptor antibodies in this autoimmune disorder
remain unknown.
H pylori may play a pathogenetic role in the develop-
ment of these two conditions. H pylori is a spiral-
shaped, flagellated, Gram-negative bacterium, which is
directly implicated in several gastrointestinal diseases
such as dyspepsia, acute and chronic gastritis, and peptic
ulceration [9]. H pylori is associated with some extra-
gastric diseases, including autoimmune diseases and
endocrine diseases. Some reports suggested that HOMA
-IR in H pylori positive patients was higher than that in
H pylori negative ones [10]. But there is only one case
available, which suggests H pylori infection could be
underlying pathological mechanism of type B insulin re-
sistance syndrome. Meanwhile, some studies suggest a
possible role of H pylori in the development of sclero-
derma [11–15]. In a much larger cohort of 124 Japanese
patents with systemic sclerosis, prevalence of anti- H
pylori antibodies was reported as 55.6 %—much higher
than that in the healthy controls [16]. Regarding to the
mechanism, It is hypothesized that H pylori induces
immune dysregulation and aggravating the course of
scleroderma [17].
The treatment of type B insulin resistance should
focus on the improvement of insulin resistance, glucose
abnormalities, and the immune disorders. The anti-
hyperglycemia therapy includes insulin therapy and oral
hypoglycemic agents. The dose of insulin needed to con-
trol hyperglycemia is typically high. Insulin sensitizers
are usually prescribed in this condition, but the efficacy
of these drugs has not been clearly studied. Nevertheless,
metformin has been reported to improve insulin resist-
ance and reduce the dose of exogenous insulin needed
to control hyperglycemia in patient with anti-insulin re-
ceptor antibodies [18]. Various immune-modulating
therapies such as corticosteroids, plasmapheresis, cyclo-
phosphamide, cyclosporine, azathioprine, mycophenolate
mofetil, and rituximab have been tried. Corticosteroids
are the most commonly used medicine to control the
autoimmune process. In addition, cyclophosphamide or
plasmapheresis has been successfully used in type B in-
sulin resistance syndrome. The patient had no response
to the combined therapy including insulin and several
oral hypoglycemic agents. Initially, a combination ther-
apy including steroids, azathioprine and tripterygium
failed to reduce the disease activity in this case. How-
ever, the patient’s blood glucose improved gradually and
skin lesions relieved after therapies aiming at H pylori
infection on the basis of combined immunotherapy.
Until now, it is unclear whether H pylori eradication im-
proves skin manifestations of scleroderma and insulin
resistance in patients. At least, in primary Raynaud’s
phenomenon, eradication of H pylori infection was re-
ported to be associated with complete remission in some
cases and relieved symptoms in most of the treated pa-
tients [19]. H pylori eradication also ameliorated type B
insulin resistance syndrome [20].
The present case suggests H pylori infection-related
pathological mechanism may contribute to type B insu-
lin resistance syndrome and autoimmune disorders. In
cases of type B insulin resistance syndrome, testing for
H pylori infection may be worthwhile and eradication of
H pylori should be considered as a therapeutic option,
which may relieve the syndrome of type B insulin
resistance.
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